Legrand N, Dixon DA, Sobolewski C. Stress granules in colorectal cancer: Current knowledge and potential therapeutic applications. World J Gastroenterol 2020; 26(35): 5223-5247 [PMID: 32994684 DOI: 10.3748/wjg.v26.i35.5223]
Corresponding Author of This Article
Cyril Sobolewski, PhD, Research Associate, Senior Scientist, Department of Cell Physiology and Metabolism, Faculty of Medicine, University of Geneva, CMU, 1 rue Michel-Servet, Geneva CH-1211, Switzerland. cyril.sobolewski@unige.ch
Research Domain of This Article
Oncology
Article-Type of This Article
Review
Open-Access Policy of This Article
This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
World J Gastroenterol. Sep 21, 2020; 26(35): 5223-5247 Published online Sep 21, 2020. doi: 10.3748/wjg.v26.i35.5223
Stress granules in colorectal cancer: Current knowledge and potential therapeutic applications
Noémie Legrand, Dan A Dixon, Cyril Sobolewski
Noémie Legrand, Department of Medicine, Faculty of Medicine, University of Geneva, Geneva CH-1211, Switzerland
Dan A Dixon, Department of Molecular Biosciences, University of Kansas, Lawrence, Kansas, and University of Kansas Cancer Center, Lawrence, KS 66045, United States
Cyril Sobolewski, Department of Cell Physiology and Metabolism, Faculty of Medicine, University of Geneva, Geneva CH-1211, Switzerland
Author contributions: Sobolewski C, Legrand N, Dixon DA contributed to the writing of the manuscript; Sobolewski C contributed to the supervision of the manuscript; Dixon DA performed the critical revision of the manuscript for important intellectual content; all authors critically revised the manuscript and approved the final version for publication.
Supported byGeneva Cancer League, No. 1711; National Institutes of Health, No. R01 CA243445; and National Cancer Institute Cancer Center Support Grant, No. P30 CA168524.
Conflict-of-interest statement: The authors declare no conflicts of interest.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Corresponding author: Cyril Sobolewski, PhD, Research Associate, Senior Scientist, Department of Cell Physiology and Metabolism, Faculty of Medicine, University of Geneva, CMU, 1 rue Michel-Servet, Geneva CH-1211, Switzerland. cyril.sobolewski@unige.ch
Received: July 22, 2020 Peer-review started: July 22, 2020 First decision: August 8, 2020 Revised: August 12, 2020 Accepted: September 3, 2020 Article in press: September 3, 2020 Published online: September 21, 2020 Processing time: 56 Days and 4.1 Hours
Core Tip
Core Tip: Colorectal cancer (CRC) represent the second cause of cancer mortality worldwide. Although changes in genetic landscape associated with CRC development have been identified, most frequent mutations are currently undruggable. The development of chemoresistance represent a major cause of CRC-associated mortality and identifying mechanisms allowing cancer cells to avoid these treatments may considerably improve clinical outcomes. Current findings indicate that cancers cells can preserve their expressed mRNAs in harmful conditions by storing them in small cytoplasmic granules, called Stress granules (SGs), where they are kept translationally silent. Targeting these SGs proteins may therefore represent a novel and efficient therapeutic approach.
